Literature DB >> 22255027

On modeling peptidomimetics in complex with the SH2 domain of Stat3.

Ankur Dhanik1, John S McMurray, Lydia Kavraki.   

Abstract

Signal transducer and activator of transcription 3 (Stat3) plays a role in human cancers. One of the main approaches towards inhibiting its activity is the development of phosphopetides or peptidomimetics that competitively bind to the SH2 domain of Stat3. This work reports, to the best of our knowledge, the first computational molecular docking study to model all of the 142 peptidomimetics that mimic the Stat3 inhibitory pTyr-X-X-Glu motif. We used the docking programs AUTODOCK and VINA to model SH2 domain-peptidomimetic complexes and estimate their binding affinities. We obtained better screening accuracy using AUTODOCK which ranked the most potent inhibitor as second highest. Experimental binding energy values and scores from docking programs correlated poorly, confirming the limitations of many current docking programs when dealing with ligands that have a large number of rotatable bonds. Nevertheless, for close to 65% of peptidomimetics, the structures of complexes computed by AUTODOCK are in agreement with current understanding of the structures. Modeling of the SH2 domain-peptidomimetic complexes is essential to better understand and design drug compounds for curing cancer. Our study is an important first step forward towards that goal.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22255027     DOI: 10.1109/IEMBS.2011.6090878

Source DB:  PubMed          Journal:  Conf Proc IEEE Eng Med Biol Soc        ISSN: 1557-170X


  2 in total

1.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012

2.  Binding modes of peptidomimetics designed to inhibit STAT3.

Authors:  Ankur Dhanik; John S McMurray; Lydia E Kavraki
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.